$XENT 90 DAYS STOCK PRICE FORECAST

Stock Price

About the Company

Intersect ENT is a global ear, nose and throat medical technology leader dedicated to transforming patient care. The Company's steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the Company's unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care. In October 2020, Intersect ENT acquired Fiagon AG Medical Technologies, a global leader in electromagnetic surgical navigation solutions with an expansive portfolio of ENT product offerings, including the VENSURE sinus balloon, that complement the Company's PROPEL® and SINUVA® sinus implants and extend its geographic reach.

CEO

Thomas West

Exchange

NASDAQ

Website

www.intersectent.com

$103M

Total Revenue

406

Employees

$899M

Market Capitalization

-13.10

Price/Earning ratio

Industry Peers

Name Ticker Market Capitalization (USD M) Revenue (USD M) Price/Book Price/Earning Net Margin (%)
Conversion Labs Inc CVLB 108548 35213 3.74 42.66 7.33
Royalty Pharma plc RPRX 19327 2239 2.87 15.52 43.40
Organon & Co. OGN 8644 7891 -4.46 4.95 22.06
Arvinas Inc ARVN 4342 21 8.14 -26.29 -782.93
Tilray Inc TLRY 3286 513 1.23 -9.74 -71.61
ATAI Life Sciences N.V. ATAI 2545 20 5.35 -11.65 -932.88
Cronos Group Inc CRON 2114 57 1.33 -14.64 -258.59
Usana Health Sciences Inc USNA 1837 1254 4.18 13.23 11.09
Phathom Pharmaceuticals Inc PHAT 1178 7.99 -7.35 None
Fulcrum Therapeutics Inc FULC 925 15 11.21 -12.53 -481.07
Intersect ENT Inc XENT 899 103 21.80 -13.10 -66.55
Phibro Animal Health Corp. PAHC 888 833 3.68 16.16 6.53
Edgewise Therapeutics Inc EWTX 848 2.87 -31.45 None
Pliant Therapeutics Inc PLRX 657 13 2.69 -7.66 -613.56
Cyteir Therapeutics Inc CYT 637 3.42 -22.04 None
Urovant Sciences Ltd UROV 503 -3.65 -3.08 None
Ikena Oncology Inc IKNA 467 10 2.52 -8.53 -551.28
Chromadex Corp CDXC 433 62 10.92 -18.30 -37.51
Rain Therapeutics Inc RAIN 404 413 2.50 -13.27 123.20
Provention Bio Inc PRVB 400 2.68 -3.12 None
Evolus Inc EOLS 321 77 4.24 -2.15 -171.53
Verrica Pharmaceuticals Inc VRCA 316 12 6.41 -8.69 -301.45
Terns Pharmaceuticals Inc TERN 263 1.46 -7.62 None
Adicet Bio Inc ACET 230 9 1.00 -4.09 -603.06
Milestone Pharmaceuticals Inc MIST 222 15 1.25 -7.50 -215.93
Kaleido Biosciences Inc KLDO 222 1 4.94 -2.49 None
LifeMD Inc LFMD 201 64 -28.62 -1.44 -133.55
Kala Pharmaceuticals Inc KALA 187 11 2.42 -1.48 None
Osmotica Pharmaceuticals Plc OSMT 181 190 2.64 -1.95 -47.85
Citius Pharmaceuticals Inc CTXR 177 2.21 -7.70 None
scPharmaceuticals Inc SCPH 162 119 2.38 -5.36 -27.05
Aquestive Therapeutics Inc AQST 146 42 -3.02 -2.27 -152.73
Eton Pharmaceuticals Inc ETON 123 15 6.11 -10.06 -74.52
Odonate Therapeutics Inc ODT 117 1.47 -1.00 None
Eyenovia Inc EYEN 113 6 12.86 -5.77 -324.94
Aerpio Pharmaceuticals Inc ARPO 99 15 2.98 -5.24 -28.77
Opiant Pharmaceuticals Inc OPNT 90 37 2.71 -86.08 -3.06
Natural Alternatives Internati NAII 89 169 1.26 10.07 5.68
VYNE Therapeutics Inc VYNE 72 16 1.08 3.27 -554.66
India Globalization Capital In IGC 67 0 2.39 -7.65 -981.18
Mannatech Inc MTEX 66 158 2.63 10.35 4.22
Acasti Pharma Inc ACST 42 0 1.81 -2.11 -611.47
Shineco Inc TYHT 36 14 1.85 -1.78 -159.60
Assertio Holdings Inc ASRT 33 117 0.45 -0.58 -38.05
Reviva Pharmaceuticals Holding RVPH 30 1.64 -4.74 None
Baudax Bio Inc BXRX 28 1 -11.98 0.84 None
Nabriva Therapeutics Plc NBRV 28 12 0.83 -0.47 -452.55
Bio-Path Holdings Inc BPTH 28 0 1.29 -2.68 18.96
Timber Pharmaceuticals Inc TMBR 26 0 11.39 0.88 -527.55
Trevi Therapeutics Inc TRVI 26 1.67 -0.74 None
Lexaria Bioscience Corp LEXX 25 1 3.49 -6.45 -445.15
Hoth Therapeutics Inc HOTH 22 1.85 -2.29 None
Cyanotech Corp. CYAN 17 34 0.99 13.57 3.83
Sonoma Pharmaceuticals Inc. SNOA 11 17 3.13 -2.04 -31.96

How Is Intersect ENT Inc. (NASDAQ: XENT) Expected To Fare In The Coming Months?

11d ago, source: marketingsentinel

Intersect ENT Inc. (NASDAQ:XENT) has a beta value of 1.63 and has seen 0.5 million shares traded in the last trading session.

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Intersect ENT, Inc. - XENT

4d ago, source: YAHOO!Finance

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at ...

Press Release: SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates SIC, XENT, INOV, SAFM; Shareholders are Encouraged to Contact the Firm

1d ago, source: Sharecast

Halper Sadeh LLP Investigates SIC, XENT, INOV, SAFM; Shareholders are Encouraged to Contact the Firm NEW YORK, Sept. 17, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, ...

INVESTIGATION: Halper Sadeh LLP Investigates XENT, INOV, GTS, IEC; Shareholders are Encouraged to Contact the Firm

2d ago, source: Law

INVESTIGATION: Halper Sadeh LLP Investigates XENT, INOV, GTS, IEC; Shareholders are Encouraged to Contact the Firm. Sep 15, 2021 11:08 AM ET. Legal Newswire POWERED BY LAW.COM . H ...

Lifshitz Law Firm, P.C. Announces Investigation of INOV, XENT, LMRK, and GTS

6d ago, source: Yahoo

by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com. Intersect ENT, Inc. (NasdaqGM: XENT) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in ...

Meeting User Needs through Combination Packaging

4d ago, source: MD&M East

In February, Intersect ENT Inc. debuted a new kit in the United States that combines the company’s new Straight Delivery System (SDS) with its Propel Mini Sinus Implant. The launch evolved from what ...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Intersect ENT, Inc. - XENT

4d ago, source: Stockhouse

Under the terms of the agreement, XENT shareholders will receive $28.25 in cash per share they own. The investigation focuses on whether Intersect ENT, Inc. and its Board of Directors violated ...

Lifshitz Law Firm, P.C. Announces Investigation of INOV, XENT, LMRK, and GTS

6d ago, source: Yahoo Finance

by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com. Intersect ENT, Inc. (NasdaqGM: XENT) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in ...

Your Portfolio